News
10.03.2021 | Company News
Neurimmune to Participate in AD/PD 2021 Virtual Conference on March 9-13, 202110.12.2020 | Company News
Neurimmune Welcomes Biogen’s News on the Filing of a New Drug Application for Aducanumab in Japan21.09.2020 | Company News
Neurimmune welcomes NovaGo Therapeutics’ appointment of Ian Metcalfe as CEO27.02.2020 | Press Release
Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy09.12.2019 | Press Release
New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS22.10.2019 | Press Release
Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab21.03.2019 | Company News
Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab